Despite the unpredictability of 2021, market activity continues. Learn what has changed—and what hasn’t—for life science companies targeting an IPO or IPO/SPAC.

The event will discuss market trends, and their impact on various paths to a public exit for life science companies and will highlight:

• Recent market conditions, including SPACs
• Regulatory developments specific to the current environment
• IPO process and timeline considerations
• Public company expectations
• Actionable insights
• Designed for C-Suite executives, legal counsel and accounting/finance leaders of pre-IPO companies.

Presented by the Cure and Deloitte.